On Friday, Shares of The Medicines Company (NASDAQ:MDCO), gained 2.26% to $43.05.
EUSA Pharma, a recently-established specialty pharmaceutical company with global reach, recently declared the appointment of William W Crouse to its Board of Directors.
Mr Crouse brings to EUSA 50 years’ experience of the life sciences industry. In his most recent role he was a General Partner at Healthcare Ventures, one of the world’s largest venture capital firms specializing in biotechnology. In addition to his 20 years’ venture capital experience, he spent 30 years in the pharmaceutical and diagnostics industry, holding roles in general administration, international operations, planned planning, licensing, acquisitions, new product development and sales and marketing. Preceding to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International.
He presently serves on the Board of The Medicines Company (MDCO), and is a Director of three private biotechnology companies. He is also a Trustee and Executive Committee Member of the New York Blood Center and is a member of Lehigh University’s Business Advisory Board. He holds a BS in Finance and Economics from Lehigh University and an MBA from Pace University.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
Shares of Dana Holding Corporation (NYSE:DAN), declined -0.35% to $17.23, during its last trading session.
Dana Holding Corporation, declared that it will supply key components to optimize the safety and performance of Joint Light Tactical Vehicles (JLTV) to be manufactured by Oshkosh Corporation for the U.S. Army and Marine Corps.
Dana will supply its Spicer central tire inflation system (CTIS), which is designed to enhance defense vehicles that require high performance all-wheel-drive and off-road mobility. The main function of Spicer CTIS is improved traction and mobility enhancement. All four tires on the vehicle can inflate or deflate quickly to the appropriate tire pressure depending on the terrain – increasing traction and enhancing the safety of troops operating the vehicle.
The performance of Spicer CTIS is optimized with a mechatronic control unit (MCU), which identifies and reacts to tire-inflation issues more effectively by enabling individual wheel control. The MCU is an integrated unit that comprises mechanical, electronic, and advanced computing capabilities for delivering improved reliability, a smaller footprint, reduced weight, and less wiring complexity.
Dana Holding Corporation manufactures and sells driveline, sealing, and thermal-administration products for vehicle manufacturers in North America, Europe, South America, and the Asia Pacific.
At the end of Friday’s trade, Shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), gained 2.60% to $6.71.
Spectrum Pharmaceuticals, declared that an overview of the Company’s business strategy and commercial and development-stage programs given at the Rodman & Renshaw 17th Annual Global Investment Conference held at the St. Regis Hotel in New York City. The Company presentation was on Thursday, September 10, 2015, at 9:35 AM ET.
Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, counting FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL.
Finally, Freescale Semiconductor Ltd (NYSE:FSL), ended its last trade with 1.45% gain, and closed at $37.03.
Freescale Semiconductor, declared the acquisition of Ottawa, Canada-based CogniVue Corporation, a leading developer of image cognition IP for automotive and consumer applications.
Freescale has established a market-leading position through developments in sensor, microcontroller and microprocessor solutions for automotive radar and vision applications. The company has shipped more than 20 million units into ADAS applications to date, and has designs in 9 of the world’s top 10 automotive OEMs. Additionally, Freescale has secured a design win pipeline enabling growth well above industry estimates for the worldwide ADAS market for the next several years.
To further fuel this growth, speed time to market and deliver even more automotive innovation for the world’s top carmakers and their suppliers, Freescale is bringing CogniVue’s advanced vision IP development capabilities and world-class R&D resources in-house.
Freescale Semiconductor, Ltd. provides embedded processors worldwide. The company’s products comprise microcontrollers, ranging from 8-bit products to higher performance 16-bit and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment or analyzing sensor inputs; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
